Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen

被引：0
|
作者：
Yukiko Onishi
Hitoshi Ishii
Tomonori Oura
Masakazu Takeuchi
机构：
[1] The Institute for Adult Diseases,Department of Diabetology
[2] Asahi Life Foundation,undefined
[3] Nara Medical University,undefined
[4] Eli Lilly Japan K.K.,undefined
[5] Medical Development Unit—Japan,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Dulaglutide; Glycemic control; GLP-1 analog; Hypoglycemia; Insulin therapy; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：735 / 745
页数：10
相关论文
共 50 条
  • [1] Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
    Onishi, Yukiko
    Ishii, Hitoshi
    Oura, Tomonori
    Takeuchi, Masakazu
    DIABETES THERAPY, 2020, 11 (03) : 735 - 745
  • [2] Efficacy and safety of once-weekly dulaglutide versus insulin glargine in combination with metformin and/or sulfonylurea in Chinese patients with type 2 diabetes
    Wang, Weiqing
    Li, Pengfei
    Gu, Liqun
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33
  • [3] Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
    Giorgino, Francesco
    Benroubi, Marian
    Sun, Jui-Hung
    Zimmermann, Alan G.
    Pechtner, Valeria
    DIABETES CARE, 2015, 38 (12) : 2241 - 2249
  • [4] Efficacy and safety of once-weekly dulaglutide versus insulin glargine in Chinese patients with type 2 diabetes and different baseline glycaemic patterns
    Hou, J.
    Zhang, B.
    Li, Q.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S287 - S287
  • [5] Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and/or a Sulfonylurea in Predominantly Asian Patients with Type 2 Diabetes
    Wang, Weiqing
    Ruiz, Luis Nevarez
    Filippova, Ekaterina
    Song, Ki-Ho
    Gu, Liqun
    Li, Pengfei
    Yang, Jun
    DIABETES, 2015, 64 : A74 - A74
  • [6] Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2)
    Giorgino, Francesco
    Benroubi, Maria
    Sun, Jui-Hung
    Zimmermann, Alan G.
    Pechtner, Valeria
    DIABETES, 2014, 63 : A87 - A87
  • [7] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Zhou, Yan
    Zhu, Jiankun
    Wu, Haiya
    Deng, Yuying
    Ji, Qiuhe
    DIABETES THERAPY, 2021, 12 (10) : 2677 - 2690
  • [8] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Yan Zhou
    Jiankun Zhu
    Haiya Wu
    Yuying Deng
    Qiuhe Ji
    Diabetes Therapy, 2021, 12 : 2677 - 2690
  • [9] Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
    Watada, Hirotaka
    Asbjornsdottir, Bjorg
    Nishida, Tomoyuki
    Nishimura, Rimei
    Yamamoto, Yuiko
    Yamauchi, Toshimasa
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2024, 26 (12): : 5882 - 5895
  • [10] Efficacy and safety of once-weekly dulaglutide monotherapy compared to glimepiride in Chinese patients with type 2 diabetes mellitus
    Wang, Weiqing
    Li, Pengfei
    Yang, Jun
    Gu, Liqun
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 10 - 11
12345